Diasorin rises with Ubs upgrade to 'Buy' and improved price target

 (Il Sole 24 Ore Radiocor) - Purchases rained down on the stock of Diasorin at Piazza Affari, which celebrated the upgrade by Ubs to 'Buy'.

Justifying the Ubs analysts' buy recommendation is the achievement of 2025 targets 'with a rich catalyst path', while the share price has suffered substantial declines in the last period. Diasorin's above-market organic revenue growth of 7 per cent over the past 18 months, according to the experts, "reflects a considered strategic shift towards underpenetrated niches".

In detail, while acknowledging that so far 2025 has been a difficult year due to difficult comparators and slower-than-expected product launches, equities are currently down 20% since the start of the year, which, analysts say, 'suggests that investors are questioning the near-term viability of the forecasts and the medium-term sustainability of the current growth rate'. Ubs believes that these concerns are 'unwarranted', as they still expect the forecasts to be achieved by the 2025 financial year (albeit at the lower end of the range). Not only that. Analysts expect growth to accelerate in 2026, with a revenue growth rate of 7% until 2030. This, "based on in-depth analysis showing that end markets are not as saturated as investors fear".

Another investor concern, the experts point out, is that the significantly above-market growth in the immunodiagnostics sector (70% of sales) is not sustainable, yet Diasorin's strategy in US hospitals 'has resulted in an above-average operating performance and still has ample room for growth in the medium term'.

For the third quarter of 2025, it expects a 'positive surprise', while, for the fourth quarter, Ubs assumes a further acceleration, with a group revenue growth rate of 9% at constant exchange rates: this supports the forecast of 8% growth in 2026.